Changed my mind on AOD-9604 — I was wrong to write it off
119 posts
Posted a year ago calling AOD-9604 useless. Standing by most of that take — it's not a meaningful fat-loss compound on its own and the obesity trial failures are real.
But a specific use case changed my mind: joint/cartilage-adjacent applications. There's a separate body of work on AOD-9604 for osteoarthritis and cartilage support that I wasn't engaging with. Ran it locally around a chronic AC joint issue for 4 weeks, pain curve moved in a way that other stuff hadn't.
So: AOD-9604 for fat loss — no. AOD-9604 as an adjunct for joint/cartilage issues — maybe, and worth a look.
Posting the update because I was confidently wrong on the second use case.
9 Replies
115 posts
Respect for the update. The cartilage/joint work on AOD is underappreciated. Still not fat-loss efficacy.
94 posts
The AC joint use case matches a niche I've seen. Local pin (not systemic) is key. Systemic AOD for joints would be diluted.
- CJC-1295 no DAC · 100 mcg · pre-bed · sub-Q
- Ipamorelin · 200 mcg · pre-bed · sub-Q
- BPC-157 · 250 mcg · 2x/day · sub-Q
14 posts
Tried AOD locally around a meniscus tear alongside BPC. Subjective improvement, hard to attribute specifically. Encouraged by your report.
205 posts
The change-my-mind posts are the best genre in this forum. Thanks for modeling it.
- CJC-1295 no DAC · 100 mcg · pre-bed · sub-Q
- Ipamorelin · 200 mcg · pre-bed · sub-Q
- BPC-157 · 500 mcg · 2x/day · sub-Q
71 posts
The Metabolic Pharmaceuticals patent literature on AOD-9604 for cartilage/OA is where this use case comes from. It's thin but directionally consistent with the emerging clinical work.
34 posts
Even as a skeptic this kind of update moves me. 'I was wrong about a narrower claim than I thought' is the most useful correction.
50 posts
Adding AOD locally to my rehab toolkit for AC joint and low-grade cartilage issues. Will report back.
- BPC-157 · 250 mcg · 2x/day local · sub-Q
- TB-500 · 2 mg · weekly · sub-Q
71 posts
The standard-issue AOD fat-loss claim is still marketing-grade nonsense. The niche joint use is different. Good clarity.
- BPC-157 · 500 mcg · 2x/day · sub-Q
- GHK-Cu · 2 mg · nightly topical · topical
46 posts